Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face

Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01024374

Acronym

13244/2009

Enrollment

Registered

2009-12-02

Start date

2010-04-30

Completion date

Unknown

Last updated

2009-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seborrheic Dermatitis

Brief summary

Clinical single-blind randomized comparison with the overall objective of evaluating the clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of seborrheic dermatitis on the face. Will be held clinical and perceived efficacy assessment and instrumental measurements. Each product will be applied at half face for 7 consecutive days and all applications will be monitored in the research site. 60 volunteers will be recruited. Evaluations will be held at the following times: T0 - before the initial application of the product; T1 - 24 hours after starting treatment, T2 - 48 hours after starting treatment, T3 - 72 hours after initiation of treatment, T4 - 96 hours after the start treatment, T7 - 7 days after initiation of treatment.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy subjects * Subjects with seborrheic dermatitis on both sides of the face * both sexes * aged 18 to 60 years * skin types I through IV.

Exclusion criteria

* pregnancy / lactation * skin condition in the area of application of the product * diabetes * immune insufficiency * subjects that are using systemic corticoids * subjects that are using immunosuppressors * skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis * history of reaction to the product category * other diseases or medications that might interfere directly in the study or endanger the health of the subject

Outcome results